Actively Recruiting
Study Comparing Verity-BCG and OncoTICE for Treating Intermediate and High-risk Non-Muscle Invasive Bladder Cancer in Patients New to BCG Treatment
Led by Verity Pharmaceuticals Inc. · Updated on 2026-03-20
540
Participants Needed
6
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying the effects of Verity-BCG in patients with intermediate and high-risk non-muscle-invasive bladder cancer NMIBC who have never been treated with intradermal or intravesical BCG before, except for childhood tuberculosis vaccination. The study aims to compare Verity-BCG to the current standard BCG treatment, OncoTICE, to see if Verity-BCG is at least as effective in preventing cancer recurrence over 24 months. This randomized, double-blind trial focuses on patients at high risk of recurrence, defined as greater than 50%, and evaluates the recurrence-free survival rates as the primary outcome.
CONDITIONS
Brief Title
Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)
Research Team
T
Taniya Mann, PhD, MBA
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
